Common germline-somatic variant interactions in advanced urothelial cancer
The role of germline variation in human cancers is not fully understood. Here, the authors define the landscape of putative deleterious germline variants that abrogate tumor suppressor proteins in advanced urothelial cancer patients.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-12-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-19971-8 |
| id |
doaj-841aaee60ec54eb68cb48ba20fbccfd4 |
|---|---|
| record_format |
Article |
| spelling |
doaj-841aaee60ec54eb68cb48ba20fbccfd42021-05-11T08:32:18ZengNature Publishing GroupNature Communications2041-17232020-12-0111111310.1038/s41467-020-19971-8Common germline-somatic variant interactions in advanced urothelial cancerAram Vosoughi0Tuo Zhang1Kyrillus S. Shohdy2Panagiotis J. Vlachostergios3David C. Wilkes4Bhavneet Bhinder5Scott T. Tagawa6David M. Nanus7Ana M. Molina8Himisha Beltran9Cora N. Sternberg10Samaneh Motanagh11Brian D. Robinson12Jenny Xiang13Xiao Fan14Wendy K. Chung15Mark A. Rubin16Olivier Elemento17Andrea Sboner18Juan Miguel Mosquera19Bishoy M. Faltas20Department of Pathology and Laboratory Medicine, Weill Cornell MedicineCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York-Presbyterian HospitalDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York-Presbyterian HospitalCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York-Presbyterian HospitalDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDivision of Medical Oncology, Dana Farber Cancer InstituteDepartment of Medicine, Division of Hematology and Medical Oncology, Weill Cornell MedicineDepartment of Pathology, Dartmouth–Hitchcock Medical CenterDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineGenomic Resources Core Facility, Weill Cornell MedicineDepartments of Pediatrics and Medicine, Columbia University, NYDepartments of Pediatrics and Medicine, Columbia University, NYDepartment for Biomedical Research, University of BernCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York-Presbyterian HospitalDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineDepartment of Pathology and Laboratory Medicine, Weill Cornell MedicineCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York-Presbyterian HospitalThe role of germline variation in human cancers is not fully understood. Here, the authors define the landscape of putative deleterious germline variants that abrogate tumor suppressor proteins in advanced urothelial cancer patients.https://doi.org/10.1038/s41467-020-19971-8 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Aram Vosoughi Tuo Zhang Kyrillus S. Shohdy Panagiotis J. Vlachostergios David C. Wilkes Bhavneet Bhinder Scott T. Tagawa David M. Nanus Ana M. Molina Himisha Beltran Cora N. Sternberg Samaneh Motanagh Brian D. Robinson Jenny Xiang Xiao Fan Wendy K. Chung Mark A. Rubin Olivier Elemento Andrea Sboner Juan Miguel Mosquera Bishoy M. Faltas |
| spellingShingle |
Aram Vosoughi Tuo Zhang Kyrillus S. Shohdy Panagiotis J. Vlachostergios David C. Wilkes Bhavneet Bhinder Scott T. Tagawa David M. Nanus Ana M. Molina Himisha Beltran Cora N. Sternberg Samaneh Motanagh Brian D. Robinson Jenny Xiang Xiao Fan Wendy K. Chung Mark A. Rubin Olivier Elemento Andrea Sboner Juan Miguel Mosquera Bishoy M. Faltas Common germline-somatic variant interactions in advanced urothelial cancer Nature Communications |
| author_facet |
Aram Vosoughi Tuo Zhang Kyrillus S. Shohdy Panagiotis J. Vlachostergios David C. Wilkes Bhavneet Bhinder Scott T. Tagawa David M. Nanus Ana M. Molina Himisha Beltran Cora N. Sternberg Samaneh Motanagh Brian D. Robinson Jenny Xiang Xiao Fan Wendy K. Chung Mark A. Rubin Olivier Elemento Andrea Sboner Juan Miguel Mosquera Bishoy M. Faltas |
| author_sort |
Aram Vosoughi |
| title |
Common germline-somatic variant interactions in advanced urothelial cancer |
| title_short |
Common germline-somatic variant interactions in advanced urothelial cancer |
| title_full |
Common germline-somatic variant interactions in advanced urothelial cancer |
| title_fullStr |
Common germline-somatic variant interactions in advanced urothelial cancer |
| title_full_unstemmed |
Common germline-somatic variant interactions in advanced urothelial cancer |
| title_sort |
common germline-somatic variant interactions in advanced urothelial cancer |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2020-12-01 |
| description |
The role of germline variation in human cancers is not fully understood. Here, the authors define the landscape of putative deleterious germline variants that abrogate tumor suppressor proteins in advanced urothelial cancer patients. |
| url |
https://doi.org/10.1038/s41467-020-19971-8 |
| work_keys_str_mv |
AT aramvosoughi commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT tuozhang commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT kyrillussshohdy commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT panagiotisjvlachostergios commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT davidcwilkes commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT bhavneetbhinder commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT scottttagawa commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT davidmnanus commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT anammolina commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT himishabeltran commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT coransternberg commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT samanehmotanagh commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT briandrobinson commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT jennyxiang commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT xiaofan commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT wendykchung commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT markarubin commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT olivierelemento commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT andreasboner commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT juanmiguelmosquera commongermlinesomaticvariantinteractionsinadvancedurothelialcancer AT bishoymfaltas commongermlinesomaticvariantinteractionsinadvancedurothelialcancer |
| _version_ |
1721450676765065216 |